Milton C. Ault III - 15 Jun 2021 Form 4 Insider Report for Alzamend Neuro, Inc. (ALZN)

Role
10%+ Owner
Signature
/s/ Milton C. Ault, III
Issuer symbol
ALZN
Transactions as of
15 Jun 2021
Net transactions value
+$676,957
Form type
4
Filing time
22 Jun 2021, 18:02:10 UTC
Previous filing
14 Jun 2021
Next filing
22 Jun 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ALZN Common Stock Purchase $17,808 +1,400 +0.03% $12.72* 5,158,455 15 Jun 2021 By Digital Power Lending, LLC F1
transaction ALZN Common Stock Purchase $120,002 +11,100 +0.22% $10.81* 5,169,555 16 Jun 2021 By Digital Power Lending, LLC F1, F2
transaction ALZN Common Stock Purchase $173,440 +16,500 +0.32% $10.51* 5,186,055 17 Jun 2021 By Digital Power Lending, LLC F1, F3
transaction ALZN Common Stock Sale $5,400 -500 -0.01% $10.80* 5,185,555 17 Jun 2021 By Digital Power Lending, LLC F3
transaction ALZN Common Stock Purchase $153,173 +16,500 +0.32% $9.28* 5,202,055 18 Jun 2021 By Digital Power Lending, LLC F1, F4
transaction ALZN Common Stock Sale $4,760 -500 -0.01% $9.52* 5,201,555 18 Jun 2021 By Digital Power Lending, LLC F1
transaction ALZN Common Stock Purchase $52,668 +6,500 +0.12% $8.10* 5,208,055 21 Jun 2021 By Digital Power Lending, LLC F1, F5
transaction ALZN Common Stock Purchase $170,027 +22,000 +0.42% $7.73* 5,230,055 22 Jun 2021 By Digital Power Lending, LLC F1, F6
holding ALZN Common Stock 15,000,000 15 Jun 2021 By Ault Life Sciences, Inc. F7
holding ALZN Common Stock 10,000,000 15 Jun 2021 By Ault Life Sciences Fund, LLC F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Digital Power Lending, LLC ("DPL") is a wholly-owned subsidiary of Ault Global Holdings, Inc. ("AGH"). Mr. Ault, the Executive Chairman of AGH, is deemed to have voting and investment power with respect to the securities held of record by DPL.
F2 The common stock was purchased by the reporting person in open market transactions on the transaction date, with a volume weighted average purchase price of $10.8110. The range of purchase prices on the transaction date was $10.76 to $10.87 per share. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price.
F3 The common stock was purchased by the reporting person in open market transactions on the transaction date, with a volume weighted average purchase price of $10.5115. The range of purchase prices on the transaction date was $10.37 to $10.85 per share. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price.
F4 The common stock was purchased by the reporting person in open market transactions on the transaction date, with a volume weighted average purchase price of $9.2832. The range of purchase prices on the transaction date was $9.22 to $9.51 per share. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price.
F5 The common stock was purchased by the reporting person in open market transactions on the transaction date, with a volume weighted average purchase price of $8.1027. The range of purchase prices on the transaction date was $8.04 to $8.24 per share. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price.
F6 The common stock was purchased by the reporting person in open market transactions on the transaction date, with a volume weighted average purchase price of $7.7285. The range of purchase prices on the transaction date was $7.65 to $7.74 per share. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price.
F7 Mr. Ault has sole voting and investment power with respect to the securities held of record by Ault Life Sciences, Inc.
F8 Mr. Ault has sole voting and investment power with respect to the securities held of record by Ault Life Sciences Fund, LLC.